Development of an ELISA for the detection of 2-nitroimidazole hypoxia markers bound to tumor tissue

Int J Radiat Oncol Biol Phys. 1992;22(3):403-5. doi: 10.1016/0360-3016(92)90841-5.


Canine and rodent tumors covalently bind the fluorinated 2-nitroimidazole, CCI-103F, in a way that immunohistochemical analysis shows is consistent with the location of tumor hypoxia. We have now developed a rapid, quantitative, and non-radioactive enzyme linked immunosorbent assay for the binding of CCI-103F in biopsy samples of spontaneous canine tumors. Issues of antigen stability during tissue processing, calibration of the ELISA, and the use of biopsy samples for measuring tumor hypoxia by the ELISA approach are addressed.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Cell Hypoxia / physiology*
  • Dogs
  • Enzyme-Linked Immunosorbent Assay*
  • Liposarcoma / physiopathology
  • Liposarcoma / veterinary
  • Neoplasms / physiopathology*
  • Neoplasms / veterinary
  • Nitroimidazoles* / metabolism
  • Sarcoma, Synovial / physiopathology
  • Sarcoma, Synovial / veterinary


  • Nitroimidazoles
  • CCI 103F